Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 4/2007

01-09-2007 | Original Article

Effect of a V-ATPase inhibitor, FR202126, in syngeneic mouse model of experimental bone metastasis

Author: Kazuaki Niikura

Published in: Cancer Chemotherapy and Pharmacology | Issue 4/2007

Login to get access

Abstract

Purpose

It has been demonstrated that vacuolar ATPase (V-ATPase) is involved in various aspects of bone metastasis. The aim of this study is to investigate the effect of the anti-bone resorptive activity of the V-ATPase inhibitor FR202126 on bone metastases in mice with metastatic breast cancer.

Method

As a spontaneous model of breast cancer metastasis to bone, mouse breast cancer cells, 4T1, were injected into the mammary fat pad in immunocompetent syngeneic mice. The mice were orally treated with FR202126 for 29 days. Tumor volume was measured once a week. Thirty days after the injection of the cells, the bone mineral density (BMD) of the proximal tibia was measured using peripheral quantitative computed tomography. Histomorphometric analysis of the distal femurs and the proximal tibiae was performed. To elucidate the mechanism behind the anti-osteolytic effect of FR202126, 4T1 cells were treated directly in vitro with FR202126. Cell viability was measured, and cell invasion was assessed using matrigel.

Results

Oral administration of FR202126 significantly increased BMD by reducing the eroded bone surface ratio. While FR202126 is known to potently inhibit osteoclast mediated bone resorption, it did not prevent invasion by cancer cells or their proliferation.

Conclusion

The V-ATPase inhibitor FR202126 was found to be effective at ameliorating osteolysis induced by metastatic breast cancer, even when the cancer cells themselves are not significantly affected by it. These results suggest that the anti-bone resorptive effect of the V-ATPase inhibitor might be useful for treating bone metastases associated with breast cancer.
Literature
1.
Aibe K, Yazawa H, Abe K, Teramura K, Kumegawa M, Kawashima H, Honda K (1996) Substrate specificity of recombinant osteoclast-specific cathepsin K from rabbits. Biol Pharm Bull 19:1026–1031PubMed
2.
Blair HC, Teitelbaum SL, Ghiselli R, Gluck S (1989) Osteoclastic bone resorption by a polarized vacuolar proton pump. Science 245:855–857PubMedCrossRef
3.
Boyd MR, Farina C, Belfiore P, Gagliardi S, Kim JW, Hayakawa Y, Beutler JA, McKee TC, Bowman BJ, Bowman EJ (2001) Discovery of a novel antitumor benzolactone enamide class that selectively inhibits mammalian vacuolar-type (H+)-ATPases. J Pharmacol Exp Ther 297:114–120PubMed
4.
Coleman RE, Rubens RD (1987) The clinical course of bone metastases from breast cancer. Br J Cancer 55:61–66PubMed
5.
Crichton MB, Nichols JE, Zhao Y, Bulun SE, Simpson ER (1996) Expression of transcripts of interleukin-6 and related cytokines by human breast tumors, breast cancer cells, and adipose stromal cells. Mol Cell Endocrinol 118:215–220PubMedCrossRef
6.
Elomaa I, Blomqvist C, Grohn P, Porkka L, Kairento AL, Selander K, Lamberg-Allardt C, Holmstrom T (1983) Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet 1:146–149PubMedCrossRef
7.
Forgac M (1989) Structure and function of vacuolar class of ATP-driven proton pumps. Physiol Rev 69:765–796PubMed
8.
Ghilardi JR, Rohrich H, Lindsay TH, Sevcik MA, Schwei MJ, Kubota K, Halvorson KG, Poblete J, Chaplan SR, Dubin AE, Carruthers NI, Swanson D, Kuskowski M, Flores CM, Julius D, Mantyh PW (2005) Selective blockade of the capsaicin receptor TRPV1 attenuates bone cancer pain. J Neurosci 25:3126–3131PubMedCrossRef
9.
Gluck SL, Underhill DM, Iyori M, Holliday LS, Kostrominova TY, Lee BS (1996) Physiology and biochemistry of the kidney vacuolar H+-ATPase. Annu Rev Physiol 58:427–445PubMedCrossRef
10.
Gutteridge DH, Ward LC, Stewart GO, Retallack RW, Will RK, Prince RL, Criddle A, Bhagat CI, Stuckey BG, Price RI, Kent GN, Faulkner DL, Geelhoed E, Gan SK, Vasikaran S (1999) Paget’s disease: acquired resistance to one aminobisphosphonate with retained response to another. J Bone Miner Res 14:79–84PubMed
11.
Hu Y, Nyman J, Muhonen P, Väänänen HK, Laitala-Leinonen T (2005) Inhibition of the osteoclast V-ATPase by small interfering RNAs. FEBS Lett 579:4937–4942PubMedCrossRef
12.
Kondo Y, Kanzawa T, Sawaya R, Kondo S (2005) The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 5:726–734PubMedCrossRef
13.
Kurtzman SH, Anderson KH, Wang Y, Miller LJ, Renna M, Stankus M, Lindquist RR, Barrows G, Kreutzer DL (1999) Cytokines in human breast cancer: IL-1alpha and IL-1beta expression. Oncol Rep 6:65–70PubMed
14.
Lagadic-Gossmann D, Huc L, Lecureur V (2004) Alterations of intracellular pH homeostasis in apoptosis: origins and roles. Cell Death Differ 11:953–961PubMedCrossRef
15.
Laitala T, Väänänen HK (1994) Inhibition of bone resorption in vitro by antisense RNA and DNA molecules targeted against carbonic anhydrase II or two subunits of vacuolar H+-ATPase. J Clin Invest 93:2311–2318PubMedCrossRef
16.
Li YP, Chen W, Liang Y, Li E, Stashenko P (1999) Atp6i-deficient mice exhibit severe osteopetrosis due to loss of osteoclast-mediated extracellular acidification. Nat Genet 23:447–451PubMedCrossRef
17.
Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen HD, Yunus F, Bell R, Body J, Quebe-Fehling E, Seaman J (2001) Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 19:558–567PubMed
18.
Manishen WJ, Sivananthan K, Orr FW (1986) Resorbing bone stimulates tumor cell growth. A role for the host microenvironment in bone metastasis. Am J Pathol 123:39–45
19.
Martinez-Zaguilan R, Lynch RM, Martinez GM, Gillies RJ (1993) Vacuolar-type H+-ATPases are functionally expressed in plasma membranes of human tumor cells. Am J Physiol 265:C1015–C1029PubMed
20.
Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ (2001) Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 61:4432–4436PubMed
21.
Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH (2006) Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 38:617–627PubMedCrossRef
22.
Niikura K, Takano M, Sawada M (2004) A novel inhibitor of vacuolar ATPase, FR167356, which can discriminate between osteoclast vacuolar ATPase and lysosomal vacuolar ATPase. Br J Pharmacol 142:558–566PubMedCrossRef
23.
Niikura K, Takeshita N, Chida N (2005) A novel inhibitor of vacuolar ATPase, FR202126, prevents alveolar bone destruction in experimental periodontitis in rats. J Toxicol Sci 30:297–304PubMedCrossRef
24.
Niikura K, Takeshita N, Takano M (2005) A vacuolar ATPase inhibitor, FR167356, prevents bone resorption in ovariectomized rats with high potency and specificity: potential for clinical application. J Bone Miner Res 20:1579–1588PubMedCrossRef
25.
Nishi T, Forgac M (2002) The vacuolar (H+)-ATPases–Nature’s most versatile proton pumps. Nat Rev Mol Cell Biol 3:94–103PubMedCrossRef
26.
Powles T, Paterson S, Kanis JA, McCloskey E, Ashley S, Tidy A, Rosenqvist K, Smith I, Ottestad L, Legault S, Pajunen M, Nevantaus A, Mannisto E, Suovuori A, Atula S, Nevalainen J, Pylkkanen L (2002) Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 20:3219–3224PubMedCrossRef
27.
Rabbani SA, Khalili P, Arakelian A, Pizzi H, Chen G, Goltzman D (2005) Regulation of parathyroid hormone-related peptide by estradiol: effect on tumor growth and metastasis in vitro and in vivo. Endocrinology 146:2885–2894PubMedCrossRef
28.
Ralston SH (1992) Medical management of hypercalcemia. Br J Clin Pharmacol 34:11–20PubMed
29.
Rogers MJ (2003) New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 9:2643–2658PubMedCrossRef
30.
Saarto T, Blomqvist C, Virkkunen P, Elomaa I (2001) Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 19:10–17PubMed
31.
Sennoune SR, Bakunts K, Martinez GM, Chua-Tuan JL, Kebir Y, Attaya MN, Martinez-Zaguilan R (2004) Vacuolar H+-ATPase in human breast cancer cells with distinct metastatic potential: distribution and functional activity. Am J Physiol Cell Physiol 286:C1443–C1452PubMedCrossRef
32.
Sennoune SR, Luo D, Martinez-Zaguilan R (2004) Plasmalemmal vacuolar-type H+-ATPase in cancer biology. Cell Biochem Biophys 40:185–206PubMedCrossRef
33.
Sun-Wada GH, Wada Y, Futai M (2004) Diverse and essential roles of mammalian vacuolar-type proton pump ATPase: toward the physiological understanding of inside acidic compartments. Biochim Biophys Acta 1658:106–114PubMedCrossRef
34.
Swallow CJ, Grinstein S, Rotstein OD (1990) A vacuolar type H+-ATPase regulates cytoplasmic pH in murine macrophages. J Biol Chem 265:7645–7654PubMed
35.
Torigoe T, Izumi H, Ise T, Murakami T, Uramoto H, Ishiguchi H, Yoshida Y, Tanabe M, Nomoto M, Kohno K (2002) Vacuolar H(+)-ATPase: functional mechanisms and potential as a target for cancer chemotherapy. Anticancer Drugs 13:237–243PubMedCrossRef
36.
Wax MB, Saito I, Tenkova T, Krupin T, Becker B, Nelson N, Brown D, Gluck SL (1997) Vacuolar H+-ATPase in ocular ciliary epithelium. Proc Natl Acad Sci USA 94:6752–6757PubMedCrossRef
37.
Yoneda T, Michigami T, Yi B, Williams PJ, Niewolna M, Hiraga T (2000) Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma. Cancer 88:2979–2988PubMedCrossRef
38.
Yoneda T, Sasaki A, Mundy GR (1994) Osteolytic bone metastasis in breast cancer. Breast Cancer Res Treat 32:73–84PubMedCrossRef
Metadata
Title
Effect of a V-ATPase inhibitor, FR202126, in syngeneic mouse model of experimental bone metastasis
Author
Kazuaki Niikura
Publication date
01-09-2007
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 4/2007
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-006-0401-8

Other articles of this Issue 4/2007

Cancer Chemotherapy and Pharmacology 4/2007 Go to the issue

Original Article

Phase I and pharmacokinetic trial of AP5346, a DACH–platinum–polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients

Original Article

Preclinical antitumor activity of the oral platinum analog satraplatin

Original Article

Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6 is associated with reduced activity for SN-38 in Japanese patients with cancer

Original Article

Trichosanthin down-regulated p210Bcr-Abl and enhanced imatinib-induced growth arrest in chronic myelogenous leukemia cell line K562

Original Article

A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic adenocarcinoma

Original Article

Influence of ketoconazole on the fecal and urinary disposition of docetaxel
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits